Clinical Trial Update: Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of microneedle arrays delivering doxorubicin for basal cell carcinoma was terminated; results were posted in August 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• D-MNA (doxorubicin microneedle array) (doxorubicin)

Snippet

Sponsor: SkinJect, Inc. | Conditions: Basal Cell Carcinoma | Phase 1 | Status: TERMINATED | Results posted: 2022-08-17